Liquidia Corp (LQDA)
10.01
-0.13
(-1.28%)
USD |
NASDAQ |
Sep 27, 16:00
10.01
0.00 (0.00%)
After-Hours: 20:00
Liquidia SG&A Expense (Annual): 44.74M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
Date | Value |
---|---|
December 31, 2023 | 44.74M |
December 31, 2022 | 32.41M |
December 31, 2021 | 23.11M |
December 31, 2020 | 27.37M |
Date | Value |
---|---|
December 31, 2019 | 13.60M |
December 31, 2018 | 8.754M |
December 31, 2017 | 10.21M |
December 31, 2016 | 4.841M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
13.60M
Minimum
2019
44.74M
Maximum
2023
28.25M
Average
27.37M
Median
2020
SG&A Expense (Annual) Benchmarks
United Therapeutics Corp | 477.10M |
Arcturus Therapeutics Holdings Inc | 52.87M |
Paragon 28 Inc | 180.02M |
Tonix Pharmaceuticals Holding Corp | 34.75M |
AIM ImmunoTech Inc | 21.14M |